New missile-like radioactive therapy treats prostate cancer
The Institute of Cancer Research (ICR) - 03-Jun-2021Precisely targeted therapy shrank tumours and extends life by 38% in men
Join the club for FREE to access the whole archive and other member benefits.
Chief Executive and President of The Institute of Cancer Research.
Professor Paul Workman FMedSci, FRS is Chief Executive and President of The Institute of Cancer Research (ICR).
Professor Workman is a passionate advocate of personalised molecular medicine and is an enthusiastic practitioner of multidisciplinary cancer drug discovery and development approaches to 'drugging the cancer genome'. He also conceptualised the 'Pharmacological Audit Trail' approach.
Visit website: https://www.icr.ac.uk/our-research/researchers-and-teams/professor-paul-workman
See also: The Institute of Cancer Research (ICR) - One of the world’s most influential cancer research organizations
Details last updated 02-Nov-2019
Precisely targeted therapy shrank tumours and extends life by 38% in men
Partnering with Japan's DSP, a milestone is reached in OCD treatment
Can speed up drug discovery process using artificial intelligence
Only 5% saw their tumours shrink, but may be more successful if used earlier
Needs to identify those who will respond to treatment before starting immunotherapy
By determining the DHX8's structure, scientists could discover new ways of cancer treatment
Highly targeted form of radiotherapy shapes radiation beams to tumours. When prostate cancer has...
circulating nanoparticles monitored with a wrist-worn sensor.